EGFR Overexpressed in Colonic Neoplasia Can be Detected on Wide-Field Endoscopic Imaging

Clinical and Translational Gastroenterology

Volumn 6, Issue 7, 2015, Pages

  Zhou, Juan ^a   Joshi, Bishnu P ^a   Duan, Xiyu ^b   Pant, Asha ^a   Qiu, Zhen ^a   Kuick, Rork ^b   Owens, Scott R ^b   Wang, Thomas D ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PEPTIDE; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COLON ADENOMA; CONTROLLED STUDY; DISEASE MODEL; ENDOSCOPE; FLUORESCENCE IMAGING; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MOUSE; NONHUMAN; PEPTIDE ANALYSIS; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PURIFICATION; PROTEIN TARGETING;

EID: 84989327933     PISSN: None     EISSN: 2155384X     Source Type: Journal    
DOI: 10.1038/ctg.2015.28     Document Type: Article

References (52)

1. Ferlay J, Soerjomataram I, Ervik M et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No 11 [Internet]. Lyon, France: International Agency for Research on Cancer. 2013.
2. Ferlay J, Shin HR, Bray F et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-2917.
3. Vogelstein B, Papadopoulos N, Velculescu VE et al. Cancer genome landscapes. Science 2013; 339: 1546-1558.
4. Seeff LC, Richards TB, Shapiro JA et al. How many endoscopies are performed for colorectal cancer screening? Results from CDC's survey of endoscopic capacity. Gastroenterology 2004; 127: 1670-1677.
5. Heresbach D, Barrioz T, Lapalus MG et al. Miss rate for colorectal neoplastic polyps: a prospective multicenter study of back-to-back video colonoscopies. Endoscopy 2008; 40: 284-290.
6. Leufkens AM, van Oijen MG, Vleggaar FP et al. Factors influencing the miss rate of polyps in a back-to-back colonoscopy study. Endoscopy 2012; 44: 470-475.
7. Rex DK, Cutler CS, Lemmel GT et al. Colonoscopic miss rates of adenomas determined by back-to-back colonoscopies. Gastroenterology 1997; 112: 24-28.
8. Muto T, Kamiya J, Sawada T et al. Small "flat adenoma" of the large bowel with special reference to its clinicopathologic features. Dis Colon Rectum 1985; 28: 847-851.
9. Rembacken BJ, Fujii T, Cairns A et al. Flat and depressed colonic neoplasms: a prospective study of 1000 colonoscopies in the UK. Lancet 2000; 8 355 1211-1214.
10. Voorham QJ, Carvalho B, Spiertz AJ et al. Chromosome 5q loss in colorectal flat adenomas. Clin Cancer Res 2012; 18: 4560-4569.
11. Soetikno RM, Kaltenbach T, Rouse RV et al. Prevalence of nonpolypoid (flat and depressed) colorectal neoplasms in asymptomatic and symptomatic adults. JAMA 2008; 299: 1027-1035.
12. Mäkinen MJ. Colorectal serrated adenocarcinoma. Histopathology 2007; 50: 131-150.
13. Citri A, Yarden Y. EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 2006; 7: 505-516.
14. Ogiso H, Ishitani R, Nureki O et al. Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell 2002; 110: 775-787.
15. Bianco R, Gelardi T, Damiano V et al. Rational bases for the development of EGFR inhibitors for cancer treatment. Int J Biochem Cell Biol 2007; 39: 1416-1431.
16. Van Cutsem E, Köhne CH, Hitre E et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360: 1408-1417.
17. Seymour MT, Brown SR, Middleton G et al. Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial. Lancet Oncol 2013; 14: 749-759.
18. Spano JP, Lagorce C, Atlan D et al. Impact of EGFR expression on colorectal cancer patient prognosis and survival. Ann Oncol 2005; 16: 102-108.
19. Porebska I, Harlozińska A, Bojarowsi T. Expression of the tyrosine kinase activity growth factor receptors (EGFR, ERB B2, ERB B3) in colorectal adenocarcinomas and adenomas. Tumour Biol 2000; 21: 105-115.
20. Bansal A, Liu X, McGregor DH et al. Correlation of epidermal growth factor receptor with morphological features of colorectal advanced adenomas: a pilot correlative case series. Am J Med Sci 2010; 340: 296-300.
21. Flora M, Piana S, Bassano C et al. Epidermal growth factor receptor (EGFR) gene copy number in colorectal adenoma-carcinoma progression. Cancer Genet 2012; 205: 630-635.
22. Rego RL, Foster NR, Smyrk TC et al. Prognostic effect of activated EGFR expression in human colon carcinomas: comparison with EGFR status. Br J Cancer 2010; 102: 165-172.
23. Fichera A, Little N, Jagadeeswaran S et al. Epidermal growth factor receptor signaling is required for microadenoma formation in the mouse azoxymethane model of colonic carcinogenesis. Cancer Res 2007; 67: 827-835.
24. Dougherty U, Sehdev A, Cerda S et al. Epidermal growth factor receptor controls flat dysplastic aberrant crypt foci development and colon cancer progression in the rat azoxymethane model. Clin Cancer Res 2008; 14: 2253-2262.
25. Liu J, Zuo X, Li C et al. In vivo molecular imaging of epidermal growth factor receptor in patients with colorectal neoplasia using confocal laser endomicroscopy. Cancer Lett 2013; 330: 200-207.
26. Mitsunaga M, Kosaka N, Choyke PL et al. Fluorescence endoscopic detection of murine colitis-associated colon cancer by topically applied enzymatically rapid-activatable probe. Gut 2013; 62: 1179-1186.
27. Bird-Lieberman EL, Neves AA, Lao-Sirieix P et al. Molecular imaging using fluorescent lectins permits rapid endoscopic identification of dysplasia in Barrett's esophagus. Nat Med 2012; 18: 315-321.
28. Hsiung PL, Hardy J, Friedland S et al. Detection of colonic dysplasia in vivo using a targeted heptapeptide and confocal microendoscopy. Nat Med 2008; 14: 454-458.
29. Sturm MB, Joshi BP, Lu S et al. Targeted imaging of esophageal neoplasia with a fluorescently labeled peptide: first-in-human results. Sci Transl Med 2013; 5: 184ra61.
30. Miller SJ, Lee CM, Joshi BP et al. Targeted detection of murine colonic dysplasia in vivo with flexible multispectral scanning fiber endoscopy. J Biomed Opt 2012; 17: 021103.
31. Padgett KA, Sorge JA. Creating seamless junctions independent of restriction sites in PCR cloning. Gene 1996; 168: 31-35.
32. Li M, Anastassiades CP, Joshi BP et al. Affinity peptide for targeted detection of dysplasia in Barrett's esophagus. Gastroenterology 2010; 139: 1472-1480.
33. Fields GB, Noble RL. Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids. Int J Pept Protein Res 1990; 35: 161-214.
34. Thomas R, Chen J, Roudier MM et al. In vitro binding evaluation of 177Lu-AMBA, a novel 177Lu-labeled GRP-R agonist for systemic radiotherapy in human tissues. Clin Exp Metastasis 2009; 26: 105-119.
35. Joshi BP, Liu Z, Elahi SF et al. Near-infrared-labeled peptide multimer functions as phagemimic for high affinity, specific targeting of colonic adenomas in vivo. Gastrointest Endosc 2012; 76: 1197-1206 e1-e5.
36. Hinoi T, Akyol A, Theisen BK et al. Mouse model of colonic adenoma-carcinoma progression based on somatic Apc inactivation. Cancer Res 2007; 67: 9721-9730.
37. Liu Z, Miller SJ, Joshi BP et al. Targeted wide-field fluorescence imaging of colonic dysplasia with near-infrared octapeptide. Gut 2013; 62: 395-403.
38. Petsalaki E, Stark A, García-Urdiales E et al. Accurate prediction of peptide binding sites on protein surfaces. PLoS Comput Biol 2009; 5: e1000335.
39. Macindoe G, Mavridis L, Venkatraman V et al. HexServer: an FFT-based protein docking server powered by graphics processors. Nucleic Acids Res 2010; 38: W445-W449.
40. Luo S, Zhang E, Su Y et al. A review of NIR dyes in cancer targeting and imaging. Biomaterials 2011; 32: 7127-7138.
41. Rowan AJ, Lamlum H, Ilyas M et al. APC mutations in sporadic colorectal tumors: A mutational "hotspot" and interdependence of the "two hits". Proc Natl Acad Sci USA 2000; 97: 3352-3357.
42. Choi YS, Yoon S, Kim KL et al. Computational Design of Binding Proteins to EGFR Domain II. PLoS One 2014; 9: e92513.
43. Ai S, Duan J, Liu X et al. Biological evaluation of a novel doxorubicin-peptide conjugate for targeted delivery to EGF receptor-overexpressing tumor cells. Mol Pharm 2011; 8: 375-386.
44. Li Z, Zhao R, Wu X et al. Identification and characterization of a novel peptide ligand of epidermal growth factor receptor for targeted delivery of therapeutics. FASEB J 2005; 19: 1978-1985.
45. Song S, Liu D, Peng J et al. Novel peptide ligand directs liposomes toward EGF-R high-expressing cancer cells in vitro and in vivo. FA S E B J 2009; 23: 1396-1404.
46. Cohen G, Lecht S, Arien-Zakay H et al. Bio-imaging of colorectal cancer models using near infrared labeled epidermal growth factor. PLoS One 2012; 7: e48803.
47. Goetz M, Ziebart A, Foersch S et al. In vivo molecular imaging of colorectal cancer with confocal endomicroscopy by targeting epidermal growth factor receptor. Gastroenterology 2010; 138: 435-446.
48. Hirsch FR, Varella-Garcia M, Bunn PA Jr et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 2003; 21: 3798-3807.
49. Bhargava R, Gerald WL, Li AR et al. EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations. Mod Pathol 2005; 18: 1027-1033.
50. Jimeno A, Tan AC, Coffa J et al. Coordinated epidermal growth factor receptor pathway gene overexpression predicts epidermal growth factor receptor inhibitor sensitivity in pancreatic cancer. Cancer Res 2008; 68: 2841-2849.
51. Reuter CW, Morgan MA, Eckardt A. Targeting EGF-receptor-signalling in squamous cell carcinomas of the head and neck. Br J Cancer 2007; 96: 408-416.
52. Hanawa M, Suzuki S, Dobashi Y et al. EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus. Int J Cancer 2006; 118: 1173-1180.